United Therapeutics Corporation $UTHR Shares Sold by Profund Advisors LLC

Profund Advisors LLC reduced its position in United Therapeutics Corporation (NASDAQ:UTHR) by 34.3% during the 3rd quarter, Holdings Channel.com reports. The firm owned 5,244 shares of the biotechnology company’s stock after selling 2,732 shares during the period. Profund Advisors LLC’s holdings in United Therapeutics were worth $2,198,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently made changes to their positions in the business. AQR Capital Management LLC grew its stake in United Therapeutics by 40.1% during the 2nd quarter. AQR Capital Management LLC now owns 1,273,161 shares of the biotechnology company’s stock worth $362,876,000 after buying an additional 364,713 shares during the last quarter. Invesco Ltd. boosted its holdings in United Therapeutics by 90.2% in the second quarter. Invesco Ltd. now owns 884,703 shares of the biotechnology company’s stock worth $254,219,000 after acquiring an additional 419,588 shares in the last quarter. Assetmark Inc. grew its stake in shares of United Therapeutics by 38.1% during the second quarter. Assetmark Inc. now owns 715,834 shares of the biotechnology company’s stock worth $205,695,000 after acquiring an additional 197,384 shares during the last quarter. Norges Bank acquired a new position in shares of United Therapeutics during the second quarter valued at about $136,453,000. Finally, Amundi raised its position in shares of United Therapeutics by 3.6% in the 2nd quarter. Amundi now owns 362,826 shares of the biotechnology company’s stock valued at $107,113,000 after purchasing an additional 12,633 shares during the last quarter. Hedge funds and other institutional investors own 94.08% of the company’s stock.

Insider Transactions at United Therapeutics

In related news, EVP Paul A. Mahon sold 8,300 shares of the firm’s stock in a transaction dated Thursday, February 5th. The stock was sold at an average price of $483.25, for a total transaction of $4,010,975.00. Following the sale, the executive vice president directly owned 36,781 shares of the company’s stock, valued at $17,774,418.25. This trade represents a 18.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, COO Michael Benkowitz sold 22,500 shares of the business’s stock in a transaction that occurred on Monday, February 2nd. The shares were sold at an average price of $470.95, for a total value of $10,596,375.00. Additional details regarding this sale are available in the official SEC disclosure. Insiders have sold 498,714 shares of company stock worth $240,366,488 over the last quarter. 10.30% of the stock is currently owned by insiders.

United Therapeutics Price Performance

NASDAQ UTHR opened at $473.12 on Tuesday. United Therapeutics Corporation has a 1 year low of $266.98 and a 1 year high of $519.99. The company has a market capitalization of $20.37 billion, a PE ratio of 17.93, a P/E/G ratio of 2.58 and a beta of 0.85. The company has a fifty day moving average of $486.61 and a 200 day moving average of $429.50.

Analyst Ratings Changes

UTHR has been the topic of several research analyst reports. Jefferies Financial Group reissued a “buy” rating and set a $575.00 target price on shares of United Therapeutics in a research report on Wednesday, November 19th. UBS Group lifted their price objective on shares of United Therapeutics from $600.00 to $645.00 and gave the stock a “buy” rating in a research note on Tuesday, January 6th. Weiss Ratings reissued a “buy (b)” rating on shares of United Therapeutics in a report on Monday, December 29th. HC Wainwright raised their target price on United Therapeutics from $500.00 to $525.00 and gave the stock a “buy” rating in a research note on Thursday, October 30th. Finally, Morgan Stanley set a $447.00 price target on United Therapeutics in a research note on Wednesday, October 29th. Eight research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company. Based on data from MarketBeat, United Therapeutics presently has an average rating of “Moderate Buy” and a consensus target price of $509.50.

United Therapeutics Profile

United Therapeutics Corporation (NASDAQ: UTHR) is a biotechnology company dedicated to the development and commercialization of unique products to address life-threatening illnesses. The company’s primary focus has been on pulmonary arterial hypertension (PAH), where it has launched several therapies designed to improve functional capacity and quality of life for patients. Its marketed products include continuous infusion treprostinil (Remodulin), inhaled treprostinil (Tyvaso), oral treprostinil (Orenitram) and tadalafil (Adcirca), each tailored to different modes of administration and patient needs.